Compare HSIC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSIC | LEGN |
|---|---|---|
| Founded | 1932 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 5.9B |
| IPO Year | 1996 | 2020 |
| Metric | HSIC | LEGN |
|---|---|---|
| Price | $74.81 | $18.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $84.50 | $63.08 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.21 | N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $13,201,995,000.00 | N/A |
| Revenue This Year | $6.15 | $46.27 |
| Revenue Next Year | $3.62 | $28.77 |
| P/E Ratio | $22.97 | ★ N/A |
| Revenue Growth | ★ 5.94 | N/A |
| 52 Week Low | $60.56 | $16.24 |
| 52 Week High | $89.29 | $45.30 |
| Indicator | HSIC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 46.94 |
| Support Level | $72.81 | $17.46 |
| Resistance Level | $79.37 | $21.58 |
| Average True Range (ATR) | 1.99 | 0.75 |
| MACD | -0.72 | 0.09 |
| Stochastic Oscillator | 8.86 | 36.86 |
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.